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SUPPLEMENT ARTICLE
Treatment as Prevention: Concepts and Challenges for
Reducing HIV Incidence
Marie A. Brault, PhD,a Donna Spiegelman, ScD,a James Hargreaves, MSc, PhD,b
Denis Nash, PhD,c,d and Sten H. Vermund, MD, PhDa
Background: Four of the largest HIV prevention trials have been
conducted in sub-Saharan Africa, enrolling hundreds of thousands of
participants in catchment areas of millions of people. The trials have
focused on community-level interventions to increase diagnosis and
initiation of antiretroviral therapy (ART) to improve health and
reduce HIV transmission. Universal test-and-treat strategies are
deployed to achieve viral suppression thereby reducing risk to
uninfected persons, known as treatment as prevention (TasP).
Purpose: We review the work that found HIV plasma load to
correlate with transmission risk, demonstrated that ART could
reduce genital tract viral expression, and showed early treatment to
be beneﬁcial for persons living with HIV, and that HIV-uninfected
sexual partners were protected from infection. We review the
seemingly inconsistent ﬁndings of the major TasP trials: the TasP
[National Agency for AIDS Research (ANRS) 12249] study in
South Africa, the SEARCH trial in Kenya and Uganda, the
Botswana Combination Prevention Project Ya Tsie study, and the
HIV Prevention Trials Network 071 (PopART) trial in Zambia and
South Africa.
Findings: All the trials reinforce the critical need to identify
approaches to optimize programs and incentivize uptake and
engagement in HIV testing and ART-based care in ways that
consistently reduce HIV transmission. That other chronic conditions
can be screened for and treated in the same infrastructures suggests
added value of HIV investments.
Conclusions: Implementation challenges are a principal frontier in
the global struggle to reduce HIV transmission and mortality using
TasP, complementing efforts to ﬁnd a cure for HIV and an effective,
deployable vaccine.
Key Words: HIV, prevention, treatment as prevention, universal test
and treat, 90-90-90 targets, HIV care continuum, randomized trials,
Africa
(J Acquir Immune Deﬁc Syndr 2019;82:S104–S112)
To accelerate HIV prevention progress, the Joint UnitedNations Programme on HIV and AIDS (UNAIDS) and the
World Health Organization (WHO) announced new goals to
jumpstart efforts to end AIDS as a public health threat in
2014–2015.1 The goal was coined “90-90-90,” with speciﬁc
goals to have 90% of all people living with HIV know their
status, 90% of all HIV-infected persons who knew their status
taking antiretroviral therapy (ART), and 90% of those on ART
being virally suppressed, all by the year 2020. The 2030 goal is
“95-95-95.” To facilitate these goals, the WHO encouraged
treatment1,2 for all persons living with HIV (PLHIV), regard-
less of their CD4+ cell counts. These goals represented a more
aggressive and streamlined approach to increasing coverage of
antiretroviral treatment (ART). They were based on recognition
that early treatment yielded better clinical outcomes, and that
Treatment as Prevention (TasP) was a viable HIV prevention
and control strategy, by preventing onward HIV transmission
(we use TasP and universal testing and treatment interchange-
ably).3 Here, we seek to present the conceptual foundation for
TasP, summarize the key ﬁndings from 4 large-scale
community-based randomized trials designed to assess the
impact of large-scale deployment of TasP on HIV trans-
mission, and discuss the challenges remaining in our under-
standing and implementation of TasP.
THE SCIENTIFIC RATIONALE FOR TasP
The virological and clinical basis for TasP was established
by 2 key studies from Quinn et al in 20004 and Fideli et al in
2001.5 These 2 observational studies followed serodiscordant
heterosexual couples in Uganda (N = 415 couples)4 and Zambia
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(N = 1022 couples)5 and found that lower viral load in the
partner living with HIV was signiﬁcantly associated with lower
risk of onward transmission to HIV-uninfected partners. In the
Ugandan study, incidence was 11.8/100 person-years,4 and in
the Zambian study, incidence was 8.6/100 person-years.5 The
Zambian study used phylogenetic analyses to conﬁrm trans-
mission pairs, excluding nongenetically linked pairs whose
transmission should not be associated with the viral load of
the HIV-infected partner. In both studies, there was no trans-
mission observed between sexual partners when the infected
partner’s viral load was low; the threshold for protection from
infection in the Zambian study was under 3000 viral copies/mL.
Subsequent studies of genital tract samples demon-
strated that treatment-induced suppression of plasma viral
load also suppressed the genital viral load, which in turn,
reduced viral shedding.6–8 These studies suggested that
reduced viral loads in plasma and the genital tract would be
likely to reduce the risk of onward sexual HIV trans-
mission. That lower viral load was associated with lower
transmission risk, and that ART-reduced genital tract viral
load led to the launch of the seminal HIV Prevention Trials
Network (HPTN) 052 trial to examine the effect of earlier
ART initiation on the risk of transmission of HIV from
HIV+ individuals to their sexual partners.9,10 Serodiscord-
ant couples from 13 sites in 9 countries were enrolled in
HPTN 052 and randomly assigned to receive either early
ART (initiation upon study enrollment) or delayed ART
(initiation after either 2 consecutive CD4+ counts ,250/
mL, which was later changed to ,350/mL as national
guidelines changed, or an AIDS-deﬁning illness). An
interim analysis of the study data in 2011 after a median
follow-up of 1.7 years found that early ART, at a median
CD4 count of 442 cells/mL, was associated with a 96%
lower risk of infection transmission compared with delayed
ART, at a median CD4 count of 221 cells/mL.10 Based on
the overwhelming beneﬁt observed with early ART, all
study participants in the delayed ART arm were offered
ART, regardless of their CD4+ count. The trial continued to
follow participants through the end of the study in 2015
and found that the overwhelming protective effect of early
ART on transmission was maintained throughout the study
period.9
As the clinical effectiveness of TasP was established
by individual-level controlled trials and modeling studies,3
researchers also examined the effectiveness of expanded
treatment in larger, uncontrolled population level studies in
such diverse settings as Western Canada11 and KwaZulu-
Natal, South Africa.12 These studies suggested that expan-
sion of ART in “real-world” uncontrolled conditions could
still produce a signiﬁcant decline in HIV incidence.11,12
TasP seemed to hold the same promise as prevention of
mother-to-child transmission (PMTCT) in which treating
an infected mother can prevent vertical HIV transmission
to the infant.13 Indeed, many lessons learned from the
PMTCT experience following the WHO recommendation
that pregnant women living with HIV be treated with ART
during and after pregnancy (Option B+) could be applied to
the logistical challenges in deploying TasP to achieve
90-90-90 goals.14
WHEN DEPLOYED AT SCALE, WHAT IS THE
EFFECTIVENESS OF TasP?
There have been 4 large-scale trials of TasP and 90-90-90
with HIV incidence endpoints 15: the TasP/ANRS 12249 trial in
South Africa,16–19 the Sustainable East Africa Research in
Community Health (SEARCH) study in Kenya and Uganda,20–27
the Botswana Combination Prevention Project (BCPP) Ya Tsie
study,28–30 and the HPTN 071 (PopART) study in South Africa
and Zambia.31–35 Each of these studies highlights different
opportunities and challenges in reaching the 90-90-90 goals
and using TasP to make meaningful reductions in HIV incidence
in sub-Saharan Africa. Details on the context and methods used
in these trials have been compiled and compared elsewhere.15
The TasP Study
The TasP (ANRS 12249) study conducted by the Africa
Centre (now within the African Health Research Institute)
employed a cluster-randomized design to assess the effectiveness
of TasP on HIV incidence in KwaZulu-Natal, South Africa,
where HIV seroprevalence has been estimated at ;30%.17
Repeated home-based HIV testing of adults was conducted in
all clusters. Clusters were randomized to either immediate ART
initiation (intervention) or initiation according to national guide-
lines (control) after HIV diagnosis. The home-based testing was
well accepted and reached the ﬁrst 90 target,19 despite challenges
reaching men. However, compared with the control arm, linkage
to care, ART initiation, and viral suppression saw only modest
increases that fell far short of the second and third 90 goals.
Speciﬁcally, linkage to care and initiation of ART among those
diagnosed was low in both arms, with 53.4% ART coverage in
the intervention arm and 52.8% in the control arm, P = 0.67.
The differences in HIV incidence between the control
and intervention groups were not substantial and were not
statistically signiﬁcant.16 During the study, 565 individuals
acquired HIV (244 in the intervention arm and 321 in the
control arm). Of these, 1 year after seroconversion, 22%
migrated out from the study area, 57% were aware of their
HIV status, 27% were actively in HIV care, 12% were on
ART, and 10% were virally suppressed. The cascade was
similar for both trial arms, except for ART coverage, which
was marginally higher in the intervention arm (15%) than the
control arm (10%).36 A key lesson learned from the TasP trial
was that the intervention did not address the critical barrier in
this setting, namely a long delay between HIV diagnosis and
ART initiation, which may have led to reduction in HIV
incidence. Individuals who had never been in HIV care before
referral were signiﬁcantly less likely to link to care than those
who had previously been in care.16 Linkage to care was also
lower among students than among employed adults, among
adults who completed some or all secondary school compared
to those with a primary school education or less, among those
who lived closer to TasP clinics, and those who were referred
to the clinic after 2 or more contacts compared to those who
were referred at ﬁrst contact. Linkage to care was higher in
adults who reported knowledge of a family member living
with HIV versus not, and among those who said that they
would take ART as soon as possible after receiving an HIV
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diagnosis versus not.16 These ﬁndings suggested that future
TasP efforts would need to develop and/or adapt approaches
to reach, engage, and retain multiple heterogenous groups.18
The SEARCH Study
The SEARCH study was conducted by a Kenya–-
Uganda–US team and embedded TasP within a more
horizontal/integrated multidisease, patient-centered care
model. The goals were to reduce HIV incidence, improve
linkage to care, and improve overall community health
compared with the usual care model of more vertical/siloed
health programming and restrictive ART usage at the time of
the study, based on CD4+ count thresholds.23 Intervention
communities received the following: community health fairs
at baseline and annually where HIV and noncommunicable
disease (NCD) screening was conducted, home-based testing
for those who did not want to be tested at fairs, immediate
ART start upon HIV diagnosis, and a patient-centered chronic
care model for HIV and NCD care, clinics with trained and
sensitized providers and ﬂexible operating hours, and mobile
phone triage and appointment reminders. Control communi-
ties received the following: health fair for testing and
diagnosis at baseline only, home-based testing upon request,
ART initiation based on national guidelines (which expanded
over time), and access to the national standard-of-care for
HIV and NCDs.26
The SEARCH intervention communities experienced
a signiﬁcant decline in mortality among both PLHIV and
HIV-uninfected individuals, as well as substantial improve-
ments in hypertension control (a key NCD target) relative to
the control communities. Viral suppression among HIV+
individuals in the intervention communities also signiﬁcantly
improved from baseline (42%) to year 3 measurements
(79.7%; RR: 1.17, 95% CI: 1.11 to 1.22, P , 0.001) relative
to the control communities (42% at baseline and 68.4% at
year 3).37 After 2 years of follow-up, there were some
disparities in the intervention communities in viral suppres-
sion based on age and sex; 76.2% of males compared with
82.2% of females (difference, 6.0%; 95% CI: 4.3 to 7.7) and
64.5% of youth aged 15–24 years compared with 81.5% of
adults older than 24 years (difference, 17.0%; 95% CI: 13.6 to
20.4) had achieved viral suppression.20 Despite the positive
outcomes measured in SEARCH intervention communities,
there was no signiﬁcant difference in the 3-year cumulative
HIV incidence rate between the intervention (0.77%) and
control (0.81%) communities (RR = 0.95, 95% CI: 0.77 to
1.17, P = 0.60).
This study is harder to interpret than the Africa Centre
TasP study; we believe, since with improved viral suppres-
sion, theory suggests that an incidence reduction should
follow. There are several hypotheses to consider as to why no
reduction in HIV incidence was achieved in SEARCH. One
hypothesis might suggest that the control communities also
received some elements of the intervention package through
the baseline health fairs, which could have increased health-
seeking behaviors, including testing and ART initiation, after
the baseline. However, the different levels of viral suppres-
sion between the arms at the end of the study argue against
this interpretation. A second hypothesis is that ART eligibility
guidelines shifted over the course of the study, with ART
eligibility becoming “near universal” within a year. The
mathematical model developed by the SEARCH team
predicted a 10% reduction in HIV incidence, which may
not have been detectable in context of possible increased
health-seeking and wider ART eligibility. This classic
dilemma of the control group beneﬁting from their participa-
tion in the study, resembling the intervention group, and
leading to bias toward the null and reduction in planned
statistical power is a hazard of multiyear prevention clinical
trials.38,39 Another potential explanation is that the new
infections in the intervention group may have arisen from
individuals never exposed to the full intervention, including
mobile populations (who also tend to be younger),40 youth,
individuals during the early stages of new infection and with
a high level of infectiousness, and/or a subset of individuals
with unsuppressed viral loads, believed to be particularly
salient for communities in Kenya.41 Newly infected individ-
uals may not yet have had an opportunity to be diagnosed,
may have tested negative on an antibody test (despite having
been recently infected), and/or may be those involved with
higher numbers of concurrently partnerships. If a high pro-
portion of all new infections arise in these situations, it may
be that an annual health fair approach may not reach enough
persons to slow transmission. One must also consider random
imbalances in the control compared with intervention clusters
that may result in bias toward the null,42 although SEARCH
had 32 clusters randomized into just 2 groups.
The BCPP: The Ya Tsie Study
The Ya Tsie study in Botswana used a pair-matched
community-randomized trial in 30 communities, with 15
communities in the intervention arm and 15 in standard of
care. Intervention communities received the following pack-
age: community mobilization to encourage HIV testing and
counseling and male circumcision, home-based and other
mobile HIV testing campaigns, linkage to care support,
scaled-up linkage to male circumcision services, and
expanded ART at government clinics to cover HIV+
individuals with either CD4 counts of .350–500 cells/mL,
or CD4+.500 cells/mL and HIV-1 RNA$10,000 copies/mL.
The standard of care communities received ART according to
national guidelines at the time of the study, that is, CD4+
#350, WHO III/IV disease, or pregnancy. In June 2016,
midway through the Ya Tsie study period, the Ministry of
Health of Botswana began offering universal ART, which
was implemented in all intervention and control communi-
ties.28 Given the shifting guidelines and the period over which
the study was conducted, the rates of ART initiation were
very similar between the intervention and control sites
throughout the study, reminiscent of arm B of the HPTN
071 (PopART) study described below.
The Ya Tsie study found a signiﬁcant 30% reduction in
HIV incidence in the intervention communities compared
with the control communities. An important difference
between the other TasP trials is Ya Tsie’s focus on
combination prevention (eg, male circumcision in addition
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to TasP). It will be important for the investigators to clarify
how they handled loss to follow-up and death in their
analysis. Bias away from the null could have occurred if
those infected disproportionately were sicker, died, or were
lost to follow-up in the intervention group, perhaps because of
stigma and heightened surveillance. There were also difﬁcul-
ties in fully enumerating all inhabited households, such that
20% of age- and residency-eligible members of enumerated
households were not enrolled. The most common reasons for
nonparticipation were absenteeism and refusal, and it is
possible that people not found or not consenting in a house-
hold might differ from enrolled participants.28 Similarly, just
as random imbalances of characteristics at baseline could
have led to a null result in SEARCH, random imbalances at
baseline could have resulted in a positive result in Ya Tsie, for
example, if the intervention group included participants with
higher baseline viral suppression, circumcision, and/or ART
coverage. Post hoc multivariable adjustment can be used to
try to conﬁrm or refute this speculation. The Ya Tsie study
ﬁnding was remarkable since Botswana programs had come
close to achieving 90-90-90 goals even at study baseline,
reducing power to detect an intervention effect.29 Neverthe-
less, the ﬁndings from Botswana suggest that it is possible to
increase ART coverage and reduce HIV incidence in a high
(29%) prevalence context, even with high baseline ART
coverage, providing important lessons for other countries in
sub-Saharan Africa.
We speculate that increased Ya Tsie study coverage
might have managed to reach persons who were marginalized
within the previous health strategies such as men or youth but
were brought into care with the Ya Tsie intervention, although
it is not yet known whether this was, in fact, the case. Key
factors contributing to Botswana’s overall extraordinary
programmatic successes have been summarized elsewhere43
and include rapid point-of-care testing, free and decentralized
access to ART, and routine access to viral load monitoring. It
will be most helpful to understand more fully the cost and
cost effectiveness of the BCPP/Ya Tsie intervention package,
the relative effectiveness of speciﬁc intervention components
(possibly varying within subgroups), and the feasibility for
successful and cost-effective intervention components to be
delivered at scale within and outside Botswana.
The HPTN 071 (PopART) Study
The HPTN 071 (PopART) study was a 3-arm cluster-
randomized trial with 21 communities in South Africa and
Zambia (Fig. 1), with a primary outcome of HIV incidence
between 12 and 36 months.44 Arm A provided the full
PopART intervention package, which included ART initia-
tion irrespective of CD4+ cell count at a local health center,
annual rounds of home-based HIV testing by community
HIV-care providers (CHiPs), active referral and/or retention
in care support by CHiPs, and referrals/enhanced linkage to
male circumcision, PMTCT, adolescent and male engage-
ment, use of community engagement boards and community
dialogue processes, and screening/treatment of tuberculosis
and sexually transmitted infections (STIs). Although CHiPs
home-based visits sought to offer testing to persons who did
not know their current HIV status, the linking and treatment
elements targeted all PLHIV whether newly diagnosed, in
care but not receiving ART, or seropositive, but out of care.
Arm B provided this same intervention package, except that
ART initiation was based on national guidelines (initially,
ART if CD4 count ,350 cells/mL), which changed to
universal ART midway through the study, at which time
arm B was identical to arm A. Arm C served as the control,
providing standard of care including ART initiation consistent
with national guidelines and treatment support from the
respective Ministries of Health aided by resources from the
US President’s Emergency Response for AIDS Relief
(PEPFAR) and others. Interim ﬁndings from this study
contributed insights on using enhanced quality assurance
measures to overcome challenges related to poor sensitivity of
community-based point-of-care testing,32 successfully scaling
up testing to reach the ﬁrst 90,33,34 and efforts to achieve the
second 90 (linkage to care).31,33,45 The ﬁnal ﬁndings revealed
that, surprisingly, there was no difference between the A and
C arms, but there was a signiﬁcant 30% decrease in new HIV
infections between the B and C arms.35 The HPTN 071
(PopART) trial included 48,301 participants in the pop-
ulation cohort used to estimate incidence rates. Baseline
HIV prevalence was 21%–22% across study arms, and
from months 12–36 of the study, 553 new HIV infections
within 39,702 person-years (py) were observed (incidence
1.4/100 py), about twice as high in women than men.35 The
adjusted rate ratio for arm A vs. C was 0.93 (95% CI: 0.74
to 1.18, P = 0.51) and arm B vs. C was 0.70 (95% CI: 0.55
FIGURE 1. Schematic outline of the cluster-randomization
approach used in HPTN 071 (PopART). Three communities
with similar characteristics (eg, HIV prevalence; urban, peri-
urban, or rural) were then randomized into study arms A, B, or
C. Four clusters of 3 communities in Zambia and 3 clusters of 3
communities in South Africa were randomized. Within each
community, an estimated 15,000–30,000 people resided from
whom an average of 1832 persons were enrolled into the
population cohort from which incidence was measured. Figure
adapted from Refs. 44, 81.
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to 0.88, P = 0.006). Viral suppression at 24 months was
72.1% in arm A, compared to 67.9% in arm B, and 62.5%
in arm C. ART coverage at 36 months did not differ in arm
A (81%) vs. arm B (80%).35
The HPTN 071 (PopART) results were surprising and
will require signiﬁcant ongoing work to better understand.
Given the similarity between the interventions delivered in
arms A and B, it is possible that the differences between these
2 arms were a chance ﬁnding, and that their combined
difference with arm C (approximately a 20% reduction in
incidence) reﬂects the key, albeit post hoc, ﬁnding of the trial.
This effect was signiﬁcant, but smaller than hypothesized.35
In addition, it is possible that there was imbalance after
randomization of the communities assigned to each arm
sufﬁciently different to confound the results. For example,
38% of arm B participants living with HIV were already on
ART at baseline, while only 31%–32% of those in the other 2
arms were. Multivariate adjusted analysis can address this
explanation. It is also possible that the immediate implemen-
tation of the full intervention in arm A overburdened the
already stretched health care infrastructure, compromising the
quality and continuity of care. The more gradual roll-out of
the intervention in arm B may have allowed clinics and staff
more time to adapt and may have results in improved quality
and retention; while other aspects of the delivery of the home-
based intervention may have more successful in arm B early
in the trial than in arm A. Although there were challenges in
reaching some key groups, particularly young adults,33 the
distribution of young people was similar across the 3 arms.
Early indications are that while migration might reduce
90-90-90 coverage, differential migration across study arms
was not apparent. As we speculate might have occurred in the
SEARCH trial, the “last unreached 25%” may be those most
responsible for a disproportionately high number of trans-
missions, preventing adequate coverage to enable the levels
of reduction in population viral load that were hoped for.
Perhaps the 3-year study duration was not long enough to
fully observe the effect of the intervention, given the low
linkage-to-care rates in the ﬁrst half of the study. It will take
careful secondary data analyses to determine the most likely
explanations for the ﬁndings across all 3 arms of the study.
MODELS OF THE DYNAMICS OF HIV TRANS-
MISSION AND TasP
STIs in general, including HIV, are not spread homo-
genously in communities.1,46–52 Persons with many and/or
concurrent sexual partners contribute disproportionately to
transmission.40,53–55 Currently, mathematical models adopt
a variety of ways to represent such individuals within models,
but this poses several challenges, especially in sub-Saharan
Africa where, for example, periods of risk vary across the life
course, and deﬁnitions of sex work are complex. The
interactions of high-risk subgroups and coverage of HIV
testing, linking to ART-based care, and viral suppression
must be examined further, since access to or utilization of
HIV testing and treatment services may differ for these
subgroups. Even if 90-90-90 metrics were achieved, fully
27% of individuals would not be virally suppressed (if 90%
were tested, 90% were on ART, and 90% were virally
suppressed, multiplicative). It is plausible, therefore, that this
hardest-to-reach minority is more inﬂuential in epidemic
dynamics and in achieving the population impact of TasP
that might have been predicted.56 Thus, models that sug-
gested that TasP would reduce community viral transmission
may have been overly optimistic.56 New models that can
better take into account heterogeneity of risk and ART
coverage may be needed to guide predictions of outcomes
for various approaches to HIV prevention.
A second potential challenge to HIV transmission
modeling is that we do not know the time that interventions
take to make an imprint on community spread of HIV.
Models assuming impact in just 2–4 years may have under-
estimated the time that it takes to actually deploy new ﬁeld
logistics and to achieve desired coverage since low- and
middle-income countries have few examples of having
actually achieved 90-90-90 coverage. Although we have no
data to back up our speculation, it is possible that studies may
have ended just as their impact might be the greatest and most
measurable. It will be helpful if completed studies estimate
and report effect modiﬁcation by time since randomization.
A third concern about the existing models is their
inattention to and/or inability to estimate in- and out-
migration. When a substantial proportion of individuals
leaves or enters a study zone disproportionately in one arm
versus another, there can be a dramatic dilution of the
intervention/treatment effect.
90-90-90 IMPLEMENTATION STUDIES
In addition to the large-scale clinical trials of TasP
described above, there have been an increasing number of
studies examining the process of implementation of the
90-90-90 goals.57–61 Such studies are an anchor of HIV
implementation science efforts, and we highlight 3 of the
larger such studies—MaxART62 in Swaziland, Project Shi-
kamana63 in Tanzania, and the SAPPH-IRe intervention in
Zimbabwe.64
MaxART was a stepped-wedge randomized trial across
14 public-sector clinical sites in Swaziland’s HhoHho
Region, which aimed to assess the impact of TasP compared
with standard of care on patient retention and viral suppres-
sion. This study examined impact of TasP on those who
initiated ART early themselves, rather than on HIV incidence
among others. Sites transitioned 2 at a time from the standard
of care to the intervention, which was early access to ART.
This study employed mixed methods and was designed to
determine the feasibility, acceptability, clinical outcomes,
affordability, and scalability of offering early ART to all
HIV+ individuals in a public-sector health system. Early
qualitative ﬁndings provided further context for challenges
associated with treatment retention for mobile populations,65
as well as the challenges associated with increasing numbers
of patients and task-shifting in public clinics.66 Results of
MaxART found that TasP modestly improved retention,
improved client perceptions of care quality, and increased
retention and viral suppression rates combined ﬁvefold, thus
establishing that rather than being harmful to patients initiated
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on ART early, this strategy is strongly beneﬁcial to them.67
Final results from MaxART are expected to be published later
in 2019.
Project Shikamana was a phase 2 community-
randomized trial of a community-based model of combination
HIV prevention to improve TasP among high-risk female sex
workers (FSWs) in the Iringa region of Tanzania.63 Partic-
ipants were recruited from entertainment venues, and time-
location sampling was used to enroll a cohort of 203 HIV+
and 293 HIV2 women. Time-location sampling entailed
identifying times when the target population gathered at
venues, constructing sampling frames of venues and daytime
units, randomly selecting and visiting venues and daytime
units, and systematically collecting information from eligible
women. The intervention package included community-led
peer education, condom distribution, and HIV testing in
accessible entertainment venues; peer navigation to facilitate
ART uptake and retention in care; sensitivity training for HIV
clinical providers; SMS to promote awareness, solidarity, and
adherence; and a community-led center with activities to
promote social cohesion and community mobilization to
address challenges speciﬁc to FSWs. Pre-exposure prophy-
laxis (PrEP) was not part of the intervention. The study
assessed feasibility and acceptance of the package as well as
preliminary effectiveness. Baseline data are available.63,68
Results presented at conferences suggest that intervention
participants were signiﬁcantly less likely to become infected
with HIV at follow-up, had lower HIV incidence, reported
more consistent condom use, and experienced less gender-
based violence compared with participants in the control
group.69,70 Final results are forthcoming.71
The SAPPH-IRe (Sisters Antiretroviral Prevention
Programme—an Integrated Response) trial was a pair-
matched, parallel, cluster-randomized study nested within
the Sisters with a Voice national sex work program in
Zimbabwe.64 The primary outcome was the proportion of
FSWs with HIV viral loads of $1000 copies/mL. An
additional 9 secondary outcomes related to aspects of
treatment and prevention intended to be affected by the
intervention were assessed. In clusters receiving the standard-
of-care, the Sisters program provided FSWs with free
condoms and contraception, free HIV testing and counseling,
STI treatment, health education, community mobilization,
and legal advice. These services were provided at drop-in
centers in primary care clinics and supported by peer
educators. Women testing HIV-positive were referred to
government clinical services. In the intervention clusters, an
enhanced version of the Sisters program was implemented.
This enhanced version provided additional community mobi-
lization activities aimed at raising awareness of the beneﬁts of
ART and PrEP, strengthened support networks to encourage
health-promoting behaviors and developing leadership skills.
In addition, ART and PrEP users were encouraged to join
a community-based Adherence Sisters program, which al-
lowed them to nominate a trusted “sister” to serve as their
adherence supporter and to attend Adherence Sisters training
together. The program also included activities to encourage
HIV testing every 6 months among HIV2 women, including
mobile phone messaging reminders. Clinical services were
also improved to enable initiation of ART or PrEP on site, in
compliance with local and international guidelines. Clinical
and social support services were delivered by clinical staff,
with text messages and follow-up phone calls used to support
clinic attendance. A representative sample for outcome
surveys was sought through respondent-driven sampling.
Between study baseline and the end of the assessment
period, the proportions of women with viral loads of $1000
copies/mL dropped in both the control (35.1% reduction) and
intervention (45.6% reduction) clusters. However, the
weighted percentage risk difference suggested little difference
between the groups. Among the secondary outcomes, the
proportions of HIV+ women who reported being aware of
their status, taking ART, and being virally suppressed all
increased, but to similar degrees between control and
intervention groups. The intervention did strengthen engage-
ment of FSWs with services but did not lower overall viral
loads in the intervention group relative to the control. Study
authors believed their results supported a conclusion that
FSWs, if supported, will access services in the public sector.
They also identiﬁed improvements that could be made in
testing and ART uptake. Since the Sisters approach did not
speciﬁcally seek to identify highly vulnerable sex workers,
they may not have reached these individuals, reducing the
impact of the intervention.
CONCLUSIONS
Large scale prevention research to assess the impact of
TasP at a community scale is complex. For example, each of
the major TasP trials contended with treatment guideline
expansion outside the intervention arm, which reduced the
power of all the studies. Given a lack of highly consistent
ﬁndings, variation in the ﬁdelity of the interventions could be
at play, with challenges in rigorous adherence to protocols
over time, process outcomes, data quality, and other critical
“on the ground” details. Indeed, in large scale observational
studies outside the trial setting, HIV treatment guideline
expansion has been shown to increase the timely uptake of
ART, especially those expansions from CD4 ,350 cells/mL
to 500 cells/mL,72 and from 500 cells/mL to universal
treatment.73 In one large study of patients enrolling in HIV
care from 6 sub-Saharan African countries, 82% of patients
initiated ART within 30 days.73 That the TasP/ANRS trial in
KwaZulu-Natal had such low linkage-to-care rates was
unfortunate given the high background incidence rates and
ability to assess the impact of TasP in a large community
setting. The suboptimally low median CD4+ cell counts at
ART initiation and a slowly improving trend74,75 suggest
a critical need for identifying and scaling implementation
strategies aimed at earlier diagnosis and more effective
linkage to care of those found to be HIV-positive. Given that
national HIV treatment guidelines have expanded to universal
treatment in nearly every country in the world,76 and that
early data from a multicountry study in sub-Saharan Africa
suggest .80% of those linked to care in SSA initiate ART
rapidly,73 it is important that the TasP trials be carefully
evaluated in more detail, with continued follow-up to garner
lessons learned around how best to implement and scale
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testing and linkage strategies that are successful at promoting
timely achievement of HIV care continuum outcomes.
Indeed, others have called for a focus on identifying strategies
for earlier diagnosis and linkage for key and underserved
populations in the sub-Saharan African region,76–78 as well as
a need for new metrics to help focus our implementation
efforts on these critical prerequisites to maintain continued
impact on HIV incidence and mortality and, ultimately, end
the epidemic (ie, for those with newly diagnosed HIV, 90%
diagnosed with CD4 .500 cells/mL, 90% enrolling in care
with CD4 .500 cells/mL, and 90% initiating ART with CD4
.500 cells/mL).75
It is puzzling that the ﬁndings from the large TasP trials
been inconsistent. TasP holds much promise for reducing
HIV incidence, as the Ya Tsie study and the arm B vs. arm C
(or post hoc combined arms A + B to arm C) comparisons in
HPTN 071 (PopART) suggest. Yet, many questions remain as
to what is needed to achieve goals for global reduction in HIV
incidence, and end the HIV epidemic. Modeling has sug-
gested the need to achieve the 90-90-90 seconds to sufﬁ-
ciently reduce HIV incidence, but these models have made
assumptions about population homogeneity that may not hold
up in real-world contexts. The HPTN 052 study may,
therefore, overestimate the potential population impact of
TasP given real-world ﬁeld logistics and inability to reach the
highest behavioral risk subset of PLHIV.
The large-scale clinical trials of TasP suggest the need
for additional data on implementation factors and process
outcomes at the individual, community, and facility levels
that could have reduced testing uptake, linkage and retention
in care, and adherence to ART. Anthropologists, sociologists,
psychologists, and health systems quality improvement ex-
perts must be engaged to learn more about why individuals
with undiagnosed HIV infection do not get diagnosed sooner,
linked to care earlier, and/or become virally suppressed.
Analogous questions arise in the use of antiretroviral oral or
topical PrEP. Social-behavioral data, qualitative assessments,
and health systems data are needed to fully understand gaps
and more effectively tailor interventions to direct individuals
into appropriate treatment or prevention modalities.79,80
Although the evidence for TasP indicates some promise,
there is considerable need for reﬁnement and targeting of
strategies that ensure implementation and achievement of
TasP and the 90-90-90 goals.
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